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Abstract: A need exists for a long-term, minimally-invasive system to 
monitor blood analytes. For certain analytes, such as glucose in the case of 
diabetics, a continuous system would help reduce complications. Current 
methods suffer significant drawbacks, such as low patient compliance for 
the finger stick test or short lifetime (i.e., 3–7 days) and required 
calibrations for continuous glucose monitors. Red blood cells (RBCs) are 
potential biocompatible carriers of sensing assays for long-term monitoring. 
We demonstrate that RBCs can be loaded with an analyte-sensitive 
fluorescent dye. In the current study, FITC, a pH-sensitive fluorescent dye, 
is encapsulated within resealed red cell ghosts. Intracellular FITC reports on 
extracellular pH: fluorescence intensity increases as extracellular pH 
increases because the RBC rapidly equilibrates to the pH of the external 
environment through the chloride-bicarbonate exchanger. The resealed 
ghost sensors exhibit an excellent ability to reversibly track pH over the 
physiological pH range with a resolution down to 0.014 pH unit. Dye 
loading efficiency varies from 30% to 80%. Although complete loading is 
ideal, it is not necessary, as the fluorescence signal is an integration of all 
resealed ghosts within the excitation volume. The resealed ghosts could 
serve as a long-term (>1 to 2 months), continuous, circulating biosensor for 
the management of diseases, such as diabetes. 
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1. Introduction 
Analysis of various blood parameters provides insight into critical aspects of a patient’s 
physiological or biochemical state, thus providing information about organ function and 
disease status. Examples of important blood parameters include pH, catecholamines, and 
glucose, which at elevated levels is linked to diabetes [1]. Changes in blood pH accompany a 
variety of diseases, such as diabetic ketoacidosis and congenital lactic acidosis [2,3]. During 
treatment, it is critical to monitor blood pH, as the treatment itself may cause an overshoot of 
the set pH value [2,4–6]. Currently, the gold standard measurement for blood pH is sampling 
of arterial blood, which is both inconvenient and difficult, especially with infants and pediatric 
patients. A secondary method for estimating blood pH is measurement of transcutaneous 
pCO2 or end tidal CO2 levels. Although hourly samples are valuable, patients may experience 
rapid changes in blood pH and require immediate treatment. Thus, a long-term, continuous 
solution, e.g. a biosensor, is requisite for more complicated and serious conditions, such as 
diabetes or diabetic ketoacidosis. 
The increasing prevalence of diabetes in the United States drives the demand for more 
effective solutions to control the disease and disease-associated complications. Although 
roughly 1 out of 10 adults have Type II diabetes today, a recent report by the CDC indicates 
that the number may rise to 1 out of 3 by 2050 [7]. Diabetes was ranked as the seventh leading 
cause of death in 2007 [8], costing an estimated $174 billion [7]. However, research has 
shown that maintaining proper blood sugar levels may prevent or delay diabetes-related 
complications [9–11]. The current standard for blood glucose monitoring, the finger stick test, 
provides only a small set (e.g., 3–7) of glucose measurements daily [12,13]. These discrete 
measurements fail to provide sufficient information about blood glucose trends throughout the 
day [14]. Furthermore, the invasiveness of this technique serves as an obstacle to proper 
control of blood glucose levels through self-monitoring [1,15]. Thus there is a demand for 
continuous, minimally-invasive sensors that provide glucose measurements that correlate to 
blood levels [15]. Because of this demand, glucose monitoring has become the most heavily 
researched application for biosensors. 
Current research into continuous, minimally invasive glucose sensors focuses on systems 
that can be implanted subcutaneously, where the sensors are in continuous contact with the 
interstitial fluid. Multiple continuous glucose monitoring systems are commercially available, 
including Abbott’s FreeStyle Navigator®, the DexComTM STS®-7, and Medtronic’s Guardian® 
Real-Time [16,17]. However, these systems are approved only for use along with the finger 
stick test and cannot be used alone to determine treatment methods [13]. These systems 
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measure glucose levels through an enzymatic reaction between glucose oxidase on the 
electrode and glucose in the interstitial fluid [14,17,18]. However, these systems require 
frequent calibrations with the standard finger stick test to account for variations in the reaction 
and diffusion kinetics [19]. Also, changes in the glucose levels of the interstitial fluid 
temporally lag those of the blood [14,17,18,20]. Generally, implanted sensors are viewed by 
the body as foreign objects, eliciting an immune response that ultimately leads to fibrous 
encapsulation and precludes proper, long-term functioning [21,22]. Although efforts to reduce 
in vivo biofouling of the continuous glucose monitoring sensors through application of 
specialized membranes have led to observed stability over the lifetime of the system [16,18], 
the implanted electrode still has an operational lifetime of only 3-7 days [14,16–18]. 
As an alternative, we propose that the sensing chemistry may be entrapped within red 
blood cells (RBCs) through the hypotonic dilution method. This method takes advantage of 
the RBC membrane’s ability to reversibly swell in response to the osmolarity of the 
extracellular environment [23–26]. In this procedure, the RBCs are placed in a low osmolarity 
solution (i.e., lysis solution) at 0°C, which causes the membranes to swell and develop pores 
that are estimated to range from 10 to 500 nm [23,24,27,28]. While the pores are open, 
hemoglobin (Hb) and other molecules within the cell and fluorescent probes as well as salts in 
the lysis solution equilibrate. Once physiological osmolarity and temperature are restored, the 
pores reseal, entrapping the fluorescent probe. These carriers exhibit biodegradability and, as 
autologous cells, biocompatibility, thereby avoiding the deleterious effects of the immune 
system response [23,25,27,29–31]. Furthermore, resealed ghosts that have been returned to 
the body are able to circulate with a lifetime similar to normal RBCs [23,25,26,32,33]. Thus 




















Fig. 1. Cartoon illustrating the RBC sensing platform concept. A small portion of blood is 
removed from the patient; the blood is washed, loaded with the analyte-sensitive fluorescent 
dye, resealed, and then transfused back into the patient. An excitation light source is then 
directed at the wrist; the emission from the resealed red cell ghosts is collected and converted 
into an analyte concentration. Clip art used with permission from Microsoft. 
Efforts to entrap chemicals within RBCs began in the early 1950s with the successful 
encapsulation of ATP (as reviewed in [23,34]) and then, in 1959, various molecular weight 
dextrans [35]. In 1973, RBCs were first used as delivery vehicles for therapeutic agents by 
two independent groups [36,37]. Since these early studies, the advantages of RBCs (e.g., 
biocompatibility, biodegradability, long life time) have continued to drive the development of 
RBC carriers for delivery of biopharmaceuticals. Several excellent reviews on drug delivery 
using RBCs as biocompatible carriers are available [29,30,38]. In general, the means of 
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delivery may be either targeted or controlled drug release; the association between drug and 
RBC is either through encapsulation or membrane binding. Using these methods, a multitude 
of drugs, including those based on amino acids, proteins, and enzymes, have been investigated 
for their use in RBC delivery systems. Recently, ICG-loaded RBCs were used to study the 
hemodynamics of the retinal capillaries and choriocapillaris [39]. However, resealed red cell 
ghosts have yet to be explored as a means of monitoring analyte levels within the blood. 
A unique property of RBCs that lends itself to biosensing is the existence of cell 
membrane transporters that provide a route to report on extracellular analyte and ion levels by 
monitoring intracellular levels. Examples of transported analytes include catecholamines, e.g., 
dopamine, noradrenaline, adrenaline [40]. Human RBCs transport glucose at a high rate 
[41,42] through the GLUT1 protein. RBC membranes of all species contain the chloride-
bicarbonate exchanger, which is one of several pathways for ion transport [43]. In this work, 
we exploit this anion exchanger: the intracellular pH equilibrates to that of the extracellular 
solution in response to changes in the hydrogen ion activity of the RBC environment. Because 
the encapsulation method does not damage the exchanger, the extracellular pH can then be 
remotely monitored by measuring the fluorescence intensity of a pH-dependent probe 
encapsulated within the RBCs [44]. 
In this paper, we report on the proof-of-concept, platform technology based upon pH that 
may be expanded to monitor other circulating analytes, such as glucose. Although beyond the 
scope of the current work, it should be pointed out that visible-wavelength, glucose-sensitive 
fluorescent dyes are available [45,46]. Compared with pH dyes, however, dyes that are 
specific for glucose are traditionally more difficult to produce, due to the tendency for cross-
reactivity with fructose. For in vivo work, the visible-wavelength, glucose-sensitive dyes can 
be adapted to emit in the NIR. The cartoon in Fig. 1 illustrates the envisioned concept in 
which a small portion (e.g., 1 unit or less) of a patient’s blood would be removed, loaded with 
the analyte-sensitive fluorescent tag(s), and transfused back into the blood stream. This 
reintroduction process would be analogous to platelet donation, in which whole blood is 
removed, processed by a cell separating machine to remove platelets, and remaining 
components returned to the donor [47]. The resealed ghosts would then circulate for the 
remainder of the 120 day lifespan, reporting on analyte levels upon excitation by an external 
light source (e.g., laser diode). 
2. Experimental section 
2.1. Chemicals 
Lysis solution components (MgCl2, EDTA, urea, and phosphate buffer), KCl, fluorescein 
5(6)-isothiocyanate (FITC), glycylglycine, NaCl, and phosphate buffered saline (PBS) were 
purchased from Sigma Aldrich (St. Louis, MO). Anti-fluorescein/Oregon Green, rabbit IgG 
was purchased from Invitrogen (Carlsbad, CA). Whole sheep blood in citrate was purchased 
from Hemostat Laboratories (Dixon, CA). FITC was reacted with 4.3-fold excess 
glycylglycine at pH 9 to form the glycylglycine-FITC conjugate. All solutions were prepared 
with deionized water, adjusted to pH 7.4 with HCl and NaOH, and stored at 4°C. 
2.2. Preparation of dye-loaded, resealed red cell ghosts 
In this preparation, RBCs are diluted ~10 times with a dye-containing solution. The resulting 
RBCs are termed ―pink ghosts‖ due to the low final concentration of entrapped Hb (i.e., 10% 
of original). Low Hb ghosts were used in these initial experiments as Hb absorbance overlaps 
with the emission of the fluorescent probe. However, future work involves the incorporation 
of NIR fluorescent probes within high Hb ghosts, providing complete functionality of the 
RBC sensors in vivo. 
Whole sheep blood was washed three times with 165 mM NaCl through centrifugation 
(10,000 x g, 3 minutes) to remove plasma proteins and leukocytes; washed, packed RBCs 
#146861 - $15.00 USD Received 2 May 2011; revised 17 Jun 2011; accepted 17 Jun 2011; published 22 Jun 2011
(C) 2011 OSA 1 July 2011 / Vol. 2,  No. 7 / BIOMEDICAL OPTICS EXPRESS  2016
were stored on ice until loading. The lysis solution (53 mls) consisted of 0.94 mM MgCl2, 1.9 
mM EDTA, 4.7 mM KH2PO4, 1 M urea, 0.947 mM glycylglycine, and 217 μM glycylglycine-
FITC conjugate. This solution was stirred in a beaker surrounded by a salt water/ice mixture 
to maintain the temperature at 0°C for the loading procedure. Once the loading solution 
cooled to ~0°C, 5 mls of packed RBCs were added in a single injection. After 10 minutes, 5 
mls of 1.65 M KCl were added to restore osmolarity. After another 10 minutes, the ghosts 
were transferred to a water bath at 37°C for 25 minutes to complete the resealing process. Free 
glycylglycine-FITC conjugate, Hb, residual leukocytes and RBC debris were removed via 
aspiration following three centrifugation cycles (10,000 x g, 8 minutes for first wash, 6 
minutes for successive washes). Resealed ghosts not immediately used were stored at 4°C in 5 
volumes of PBS. 
2.3. Sensor response and spectral data acquisition 
For pH experiments, 100 mM NaOH and HCl solutions were prepared in 165 mM NaCl to 
maintain the osmolarity of the local RBC environment. Resealed ghosts were added into 
room-temperature, isotonic NaCl until a sufficient fluorescence signal could be measured with 
the optical system. As ~90% of the Hb had been removed while making the resealed ghosts, 
10 mM PBS was added to the resealed ghost solution to prevent large fluctuations in the 
extracellular pH. 
Multiple optical systems were used to acquire the data presented in this paper: 
Dynamic data: A frequency doubled Ti:sapphire laser (~15 mW, Mira 900, Coherent, 
Santa Clara, CA) served as the excitation source (λ ~440 nm) for the resealed ghosts (λex,max = 
492 nm). A short-pass filter was placed just after the doubling crystal to remove remaining 
excitation light (880 nm). Fluorescence emission (λem,max = 518 nm) was collected at 90° with 
a spectrograph (Acton SpectraPro 2300i, Princeton Instruments, Trenton, NJ) attached to a 
CCD camera (PIXIS 100, Princeton Instruments, Trenton, NJ). For time-course 
measurements, the fluorescence signal was integrated over 500–570 nm. The pH probe was 
placed in the extracellular solution to simultaneously monitor extracellular pH throughout the 
entire experiment. All pH data was collected through HyperTerminal on the PC. 
Static data: Fluorescence emission was collected with a fluorimeter (PTI, Birmingham, 
NJ) using an excitation wavelength of 488 nm. For time-course measurements, the 
fluorescence emission of a single wavelength (i.e., 514 nm) was recorded for 20 to 30 
seconds. Extracellular pH of the experimental solution of resealed ghosts was continuously 
measured with a pH probe (Orion 3 Star, Thermo Electron Corporation, Waltham, MA). Prior 
to data collection, anti-fluorescein antibody was added to the experimental solution to bind 
any free (i.e., extracellular) glycylglycine-FITC conjugate, quenching its contribution to the 
fluorescence signal. The fluorescence emission of a 1 ml sample of the experimental solution 
was recorded; the corresponding pH was recorded and the sample returned to the experimental 
solution. The pH of the experimental solution was adjusted, solution thoroughly mixed, and 
the measurements were repeated for several pH steps. 
For the emission spectra of free glycylglycine-FITC conjugate and resealed ghosts 
presented in this paper, the samples were excited using a 488 nm argon ion laser (model 163-
M12, 25 mW, Spectra-Physics Lasers, Santa Clara, CA). Fluorescence intensity was collected 
using the spectrograph/CCD camera setup described in the dynamic data section. 
Testing of sensor integrity: To allow for comparison of intensity changes due to potential 
glycylglycine-FITC conjugate release, the fluorescence intensity value at 514 nm was 
collected for 30 seconds. The fluorescence contribution of extracellular glycylglycine-FITC 
conjugate was quenched by addition of an anti-fluorescein antibody. After the experimental 
time period of 30 minutes, the intensity value at 514 nm was collected for an additional 30 
seconds. A second aliquot of the anti-fluorescein antibody was added and thoroughly mixed 
with the resealed ghosts. A third fluorescence time-based scan was recorded for 30 seconds 
for comparison. 
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3. Results and discussion 
Fluorescein has a pKa of 6.4, leading to pH-dependent fluorescence emission over the range 
of pH 5 to 9. For the experiments presented here, the fluorescein derivative, FITC, was 
conjugated to glycylglycine, rendering a cell impermeant compound—a requisite for stable 
encapsulation. The spectra of resealed ghosts and free glycylglycine-FITC conjugate (λex = 
488 nm) are compared in Fig. 2. Encapsulation of the fluorescent dye within the RBCs does 
not alter its emission curve. 
 
Fig. 2. Comparison of fluorescence spectra of resealed ghosts (black) and free glycylglycine-
FITC conjugate (grey) show that emission characteristics of the two solutions are nearly 
identical. 
To investigate the fluorescence intensity response to pH, acid or base was added in 1 to 5 
μl aliquots to vary the pH of the resealed ghost environment between pH 6.5 and 8.5. The 
resealed ghost solution was thoroughly mixed after each addition. For the dynamic data, the 
fluorescence intensity and pH signals were allowed to plateau prior to each acid/base addition 
to ensure that the resealed ghosts had sufficient time to equilibrate. The response time, defined 
as the length of time required for the signals to reach a steady state value, was typically less 
than one minute. This response time most likely reflects the response time of the electronics 
and mixing time of the solution as the chloride-bicarbonate exchange system has a half time 
of less than 1 second at 37°C [48]. In the portion of the dynamic data shown in Fig. 3, 
fluorescence intensity (integrated from 500 to 570 nm) tracks extracellular pH throughout the 
pH range of interest. The two curves exhibit similar characteristics in response to pH changes, 
including directionality, drift, and signal change for corresponding changes in pH values. The 
sensors demonstrate reversibility across the pH range throughout the 25 minutes of optical 
interrogation time (e.g., two pH measurements of approximately 7, separated by 9 
measurements over 16 minutes, had identical fluorescence intensity measurements within the 
experimental error of the system). This reversibility indicates that the optical system does not 
affect the membrane transporters or significantly photobleach the fluorescent probe. For the in 
vivo application of this sensor, the fluorescent probe would be subject to a significantly 
shorter excitation time (i.e., approximately 1 minute, or the response time of the sensor), and 
since the RBCs mix during circulation through the body, one would not expect that the same 
resealed ghosts would be found within the excitation volume for consecutive measurements. 
Thus, it is easy to envision that similar reversibility would be expected over the lifetime of the 
sensor. 
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 Fig. 3. A representative portion of a pH trial performed on the dynamic system. Fluorescence 
intensity (grey) of the intracellular pH-sensitive dye (FITC) tracks extracellular pH (black). 
The potential release of glycylglycine-FITC conjugate was investigated to evaluate the 
integrity of resealed ghosts over the experimental time period (i.e., 30 minutes). In repeated 
testing, the extent of the subsequent decrease in the measured fluorescence signal due to the 
first antibody addition varied between 9% and 46%. This variation in the signal contribution is 
directly related to how well the resealed ghosts are washed at the end of the preparation step 
(i.e., removal of free glycylglycine-FITC conjugate); more thorough washing will lead to a 
decrease in the measured contribution of free glycylglycine-FITC conjugate. Measured 
fluorescence intensities before and after the second addition of anti-fluorescein antibody (after 
30 minutes) were the same value within experimental error, indicating no significant amount 
of extracellular glycylglycine-FITC conjugate. Thus we assume the RBC membranes did not 
release glycylglycine-FITC conjugate during the pH experiments. 
A pH trial performed on the static optical system is shown in Fig. 4. After quenching of 
the extracellular glycylglycine-FITC conjugate fluorescence contribution, extracellular pH 
was monitored with the fluorescence-based sensors. After each pH change, the fluorescence 
signal at 514 nm was monitored for 30 seconds to provide sufficient data to develop an 
average fluorescence signal at each pH; the pH was recorded for each pH step. This system 
shows similar reversibility as the dynamic system, indicating that this system does not 
negatively affect the RBC membranes. 
After data collection, fluorescence intensity and corresponding pH values were selected 
for each signal plateau of the two pH trials (Fig. 3 and Fig. 4) to evaluate the sensor’s ability 
to monitor extracellular pH as a function of the measured fluorescence intensity (Fig. 5). Both 
data sets were normalized at pH 7.4. The normalized sensitivity attained by the sensors was 
0.44 per pH unit. For the dynamic system in Fig. 3, the normalized standard deviation was 
0.002, leading to a resolution, defined as the smallest change in pH discernable from the 
fluorescence intensity data, of 0.014 pH unit. For the static system in Fig. 4, the normalized 
standard deviation was 0.0143, leading to a resolution of better than 0.1 pH unit. The 
decreased resolution of this system compared with the dynamic system is primarily attributed 
to electronic noise of the fluorimeter rather than to poor performance of the sensors since, for 
a sample of glycylglycine-FITC conjugate, the normalized standard deviation of the 
fluorimeter is 0.0149. The fluorescence intensity of the resealed ghosts shows a linear 
dependence between pH 6.5 and ~7.4. At higher pH values, the response becomes nonlinear, 
as expected for a dye with pK ~6.4. From these data, the pKs for the two resealed ghost sets 
were determined to be 6.65 and 6.59. These values vary slightly from the experimental pK of  
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 Fig. 4. Fluorescence intensity responds to pH changes using the static system in which 
extracellular glycylglycine-FITC conjugate fluorescence is quenched by the anti-fluorescein 
antibody. Each segment is the middle 15 seconds of a 30 second fluorescence monitoring 
period. The grey lines indicate discontinuous data. The average pH is directly above each 
segment. 
 
Fig. 5. Normalized fluorescence intensity as a function of pH for the pH trials shown above in 
Fig. 3 () and Fig. 4 (). The two trials agree well. Error bars represent one standard 
deviation. 
glycylglycine-FITC conjugate (pK 6.37), indicating that slight effects of the resealed ghost’s 
cytosolic environment may exist. However, the resealed ghosts clearly track changes in 
extracellular pH over the physiological range. 
The distribution of glycylglycine-FITC conjugate among the resealed ghosts was 
investigated through epifluorescence (λex = 488 nm, 60x objective) and bright-field phase 
microscopy (60x objective), as shown in Fig. 6. Comparison of same field images of resealed 
ghosts taken with each of these techniques indicates that approximately 50% of the resealed 
ghosts contained the fluorescent dye (unloaded RBCs are not observable in the fluorescent 
micrograph). This observation matches well with observations of Bodemann et al. indicating 
that ~60% of ghosts made at 0° reseal upon warming to 37° [49]. Across batches, entrapment 
efficiency, defined as the ratio of loaded, resealed ghosts to total RBCs, ranged from 30 – 
80%. Although complete loading is ideal, it is not necessary for success of the sensor because 
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(1) the fluorescence signal is an integration of all resealed ghosts within the excitation volume 
and (2) unloaded RBCs do not contribute to the background signal. The final sensor design 
will include a reference fluorophore to account for variations in loading between batches, as 
well as in excitation and detection efficiencies. 
 
    (a)              (b)  
Fig. 6. Representative (a) bright-field phase and (b) epifluorescence micrographs of resealed 
ghosts loaded with glycylglycine-FITC conjugate. (Scale bar represents 5 μm.) 
4. Conclusions 
RBCs offer a unique system for entrapping fluorescence-based sensing assays that protects the 
sensor from the damaging effects (e.g., biofouling) of the immune system. Furthermore, since 
normal RBCs live for 120 days, the red cell sensors have the potential to function for multiple 
months, significantly improving on current monitoring systems. In this work, we have shown 
that dye-loaded, resealed ghosts track changes in extracellular pH. Fluorescence intensity 
changes in response to pH were reversible, and the resealed ghost membranes were stable 
over the experimental time period. While it was shown that not all RBCs load during the 
procedure, complete loading, although a long-term goal, is not a requisite for success of this 
sensing system. 
This platform technology offers the potential for a long-term, minimally-invasive method 
for monitoring blood analytes. Although the current system focuses on monitoring pH, the 
pH-sensitive dye could be replaced with a dye that is sensitive to a different analyte of 
interest, such as glucose. Since human RBCs rapidly transport glucose across the membrane, 
we expect that intracellular levels would track extracellular levels, similarly to the pH work 
shown here. Future work will focus on designing an RBC-based sensing system suitable for in 
vivo application through three specific avenues: (1) preparation of ghosts with near-normal Hb 
levels, thereby providing complete functionality in vivo; (2) incorporation of NIR dyes, where 
scattering and absorption of tissue/Hb are less significant, thereby increasing the excitation 
signal to the dye and emission signal to the detector, and (3) optimization of loading 
parameters to maximize loading homogeneity and efficiency, thereby maximizing the signal 
from the loaded ghosts. 
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